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Cancer cachexia is a severe wasting syndrome char-
acterized by the progressive loss of lean body mass
and systemic inflammation. It occurs in approxi-
mately 80% of patients with advanced malignancy
and is the cause of 20% to 30% of all cancer-related
deaths. The mechanism by which striated muscle loss
occurs is the tumor release of pro-inflammatory cy-
tokines, such as IL-1, IL-6, and TNF-. These cytokines
interact with their cognate receptors on muscle cells
to enhance NF-B signaling, which then mediates
muscle loss and significant cardiac dysfunction. Ge-
netic inhibition of NF-B signaling has demonstrated
its predominant role in skeletal muscle loss. There-
fore, we tested two novel drugs designed to specifi-
cally inhibit NF-B by targeting the IB kinase (IKK)
complex: Compound A and NEMO binding domain
(NBD) peptide. Using an established mouse model of
cancer cachexia (C26 adenocarcinoma), we deter-
mined how these drugs affected the development of
tumor-induced cardiac atrophy and function. Echo-
cardiographic and histological analysis revealed
that both Compound A and NBD inhibit cardiac
NF-B activity and prevent the development of tu-
mor-induced systolic dysfunction and atrophy. This
protection was independent of any effects of the
tumor itself (Compound A) or tumor-secreted cyto-
kines (NBD). This study identifies for the first time,
to our knowledge, that drugs targeting the IKK com-
plex are cardioprotective against cancer cachexia–
induced cardiac atrophy and systolic dysfunction,suggesting therapies that may help reduce cardiac-
associated morbidities found in patients with ad-
vancedmalignancies. (Am J Pathol 2011, 178:1059–1068;
DOI: 10.1016/j.ajpath.2010.12.009)
Cancer cachexia is a severe wasting syndrome char-
acterized by the progressive loss of lean body mass
and fat. It occurs in as many as 80% of patients with
advanced malignancy, and accounts for an estimated
20% to 30% of all cancer-related deaths.1–3 There are
essentially no therapies currently available that can be
used broadly to prevent the high morbidity associated
with cancer cachexia. In the present study, we inves-
tigate two novel compounds that selectively inhibit
NF-B to determine whether they can prevent the car-
diac sequelae of cancer cachexia using an established
mouse model of cancer cachexia.
The C26 adenocarcinoma model of cancer cachexia
was established in 1975 to create a model system that
could be used to test biological and chemotherapies in
vivo.4 Over the past three decades, it has been widely
used to delineate the natural history of carcinoma-in-
duced cachexia and antitumor therapies in vivo, as re-
cently reviewed by Aulino et al, 2010.5 This model has
been used to carefully characterize mechanisms of can-
cer cachexia, which has been found to closely parallel
human disease. Specifically, the C26 adenocarcinoma
cells can be placed in mice, where they form tumors that
secrete proinflammatory cytokines. Initial studies found a
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AJP March 2011, Vol. 178, No. 3prominent role of IL-6, but later studies identified that, in
addition to IL-6, TNF- and IL-1 can be identified circu-
lating in vivo.6,7 These proinflammatory cytokines interact
with their cognate receptors on muscle to activate the
transcription factor NF-B.8 Although these cytokines in-
teract with their own unique receptors, these receptors
have in common this activation of NF-B. Recent stud-
ies have identified that NF-B activation up-regulates
the ubiquitin-dependent degradation of the sarcomere,
which is central to the pathophysiology of striated mus-
cle atrophy. For example, the use of dominant-negative
IKK/-GFP, which inhibits NF-B, markedly reduces
the atrophy induced by disuse (up to 70%) in vivo.9
Pharmacological and genetic inhibition of NF-B simi-
larly inhibits atrophy, in part by inhibiting the expres-
sion of ubiquitin ligases, including MuRF1 and
Atrogin-1, that mediate muscle atrophy.10 Proinflam-
matory cytokines such as IL-1, IL-6, and TNF- interact
with their cognate receptors on muscle to initiate NF-
B, which regulates the degradation of the sarcomere,
resulting in muscle atrophy.11,12 These mechanisms
parallel findings in the C26 adenocarcinoma model
used in the current studies. The C26 model has been
used to identify specific alterations in myofibrillar pro-
teins in skeletal muscle during atrophy,13 the selective
degradation of myosin,14 the down-regulation of dys-
trophin,15 and the participation of Peg3/PW1 and p53
in cancer-induced muscle atrophy.16 Anti-muscle
wasting therapies have also been tested in the C26
model, including indomethacin, ibuprofen, appetite
stimulants,17,18 IL-27 treatment,6,19 myostatin,20 eryth-
ropoietin,21 exercise,22 and high-protein diets.23
Recent studies have described therapeutic interven-
tions that specifically target only acute increases in
NF-B, without affecting basal NF-B activities. They
have been shown to be useful experimentally in car-
diac ischemia reperfusion injury and in reversing car-
diac hypertrophy in vivo. In the present study, we test
the hypothesis that Compound A and NEMO binding
domain (NBD) peptides, two novel specific NF-B in-
hibitors targeting the IB kinase (IKK) complex, can
prevent C26 adenocarcinoma–induced cardiac atro-
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*phy and dysfunction.Materials and Methods
Cell Lines
The transplantable C26 colon adenocarcinoma cells13,24
were maintained and implanted as previously described
in our laboratory.25
Experimental Protocol
Seventy-five male BALB/c mice were obtained from the
Charles River Laboratories (Wilmington, MA). In our
first set of studies (Group A), 36 mice aged 43 to 63
days (weight 22 to 24 g) were evenly and randomly
divided into groups: healthy control mice, tumor-bear-
ing mice (dimethyl sulfoxide [DMSO] sham or mutant
NBD peptide [500 g] sham), tumor-bearing plus NBD
peptide (80 g, 200 g, or 500 g), and tumor-bearing
plus Compound A (2 mg/kg, 5 mg/kg, or 10 mg/kg).
Mice were housed five animals per cage in a temper-
ature-controlled room on a 12-hour light:dark cycle. All
animals had access to unlimited food and water. Mice
were allowed to acclimate to their new environment for
approximately 3 days before beginning the study.
On day 0, the mice in tumor-bearing groups were
injected subcutaneously in the right flank with 100 l
(approximately 500,000 cells) of C26 adenocarcinoma
cells. Body weight, tumor volume, and food consump-
tion were measured every other day from inoculation to
completion of the study. One animal in the tumor-bear-
ing group was sacrificed early due to tumor volume in
excess of Institutional Animal Care and Use Committee
(IUCAC) guidelines. On day 6, tumor-bearing mice be-
gan receiving single intraperitoneal injections of NBD
peptide, Compound A, mutant NBD peptide, or sterile
DMSO, based on their respective intervention, dosage,
and dosing schedule (Figure 1A). On day 17, tumor-
bearing mice had a significant tumor burden with clin-
ical signs of cachexia and underwent cardiac echocar-
diography. In our second group of studies (Group B),
27 age-matched (to Group A) mice were used in echo-
cardiographic and cardiac perfusion studies de-
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Figure 1. Inhibition of NF-B with the NEMO-bind-
ing domain (NBD) peptide and Compound A inhib-
its C26 adenocarcinoma tumor-induced cachexia.
The C26 adenocarcinoma cell line was injected at
day 0, allowed to grow in vivo for 6 days before the
development of cachexia, at which point daily treat-
ment was begun. Both NBD and Compound A treat-
ment inhibited the loss of body mass as determined
by carcass weight (A and B, respectively). A one-
way analysis of variance was performed to deter-
mine significance, followed by a multiple compari-
son procedure (Holm-Sidak method) to determine
significance between groups. *P 0.05 versus tumor
on day 17. (n  4/group, 36 total, Group A outlined
in the Materials and Methods section).m (Tumor)
 A 2 mg/kg
 A 5 mg/kg
 A 10 mg/kg
8 1scribed below (n  3 to 6 per group as outlined in
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third set of studies (Group C), 12 mice were used in
echocardiographic evaluations of drug therapies in the
absence of tumor (Supplemental Table S2 at http://ajp.
amjpathol.org). In our last group of studies (Group D),
15 mice (three mice per group) were assayed for cir-
culating cytokines.
At the completion of echocardiography or perfusion
studies, all animals were euthanized. A final total body
weight measurement was obtained. Tumors were re-
sected, measured, and weighed, and a total carcass
weight (total body weight minus the tumor weight) was
calculated. Hind limbs were weighed separately. Heart
muscle was excised from each animal immediately after
sacrifice, snap frozen in liquid nitrogen, and stored at
80°C. All animal protocols were reviewed and in com-
pliance with the IACUC.
Echocardiography
Echocardiography was performed on conscious mice us-
ing a VisualSonics Vevo 770 ultrasound biomicroscopy
system (VisualSonics, Toronto, ON, Canada) as previ-
ously described.26,27
Real-Time PCR Determination of mRNA
Expression
Total RNA was isolated from cardiac ventricular tissue as
previously described.26 Briefly, mRNA expression was de-
termined using a two-step reaction. cDNA was made using
a High-Capacity cDNA Archive Kit (Applied Biosystems,
Foster City, CA). PCR products were amplified on an ABI
Prism 7900HT Sequence Detection System using cDNA
and the TaqMan probe set in TaqMan Universal PCR Mas-
ter Mix (Applied Biosystems). The TaqMan probes used in
these studies included ANF (Mm01255747_g1), MHC
(Mm00600555_m1), BNP (Mm00435304_g1), smooth mus-
cle -actin (Mm00808218_g1), MuRF1 (Mm01188690_
m1), Atrogin-1/MAFbx/Fbxo32 (Mm00499518_m1), Nfk-
bia (Mm00477798_m1), and 18S (Hs99999901_s1) (Ap-
plied Biosystems).
Histology and Lectin Staining
Hearts were perfused with 4% paraformaldehyde in PBS
and processed for histology and stained with H&E, Mas-
son’s Trichrome, or Triticum vulgaris lectin TRITC conjugate
as previously described.26–29 Myocyte cross-sectional area
was determined on lectin-stained sections using NIH Image
J (Version 1.38X) based on parallel photomicrographs of a
standard graticule ruler. Each cross-sectional area was de-
termined from 300 measurements per group from at least
10 sections from three mice per group.
NF-B ELISA Assay
Nuclear extracts were isolated from cardiac ventricles
immediately after harvest using a commercially availablenuclear extraction kit (Cayman Chemical, Ann Arbor, MI).
Samples were homogenized using a glass tissue homog-
enizer (Kimble-Kontes, 885450-0022; Fisher Scientific,
Waltham, MA), and nuclear extracts were then isolated
according to the manufacturer’s protocols and stored at
80°C. Fifteen micrograms of ventricular nuclear ex-
tracts were then assayed for NF-B (p65) activity. NF-B
activity was determined using an ELISA assay based on
the manufacturer’s protocol (Cayman Chemical). Briefly,
this assay utilizes a specific double-stranded DNA se-
quence containing a NF-B response element immobi-
lized to a 96-well plate. Isolated nuclei from each animal
were added to the wells in triplicate, allowing nuclear
transcription factors to bind to NF-B response elements.
After capture, an antibody specific for the p65 NF-B
subunit is used to identify the presence of p65 in the
nucleus, indicative of activity. The activity of the samples
was calculated relative to experimental control using the
following formula: (sample average  average of non-
specific binding wells, OD450)/(control average, OD450 
NSB average). Four animals per group were used, and all
assays were performed in triplicate.
Multiplex Cytokine Analysis
At the completion of the experiment, before euthanasia,
approximately 200 l of blood was collected via a sub-
mandibular bleed from each mouse. The blood was al-
lowed to clot at room temperature for 1 hour, serum was
separated by centrifugation, and then stored at 80°C
until analysis. Serum cytokine and chemokine concentra-
tions were determined using a custom Bioplex Protein
Array system (BioRad, Hercules, CA). For each cytokine,
the minimum detectable concentration was 10 pg/ml.
Statistical Methods
Results are presented throughout as group mean values
plus or minus SE. The significance of observed differ-
ences in group mean values was determined using anal-
ysis of variance with Holm-Sidak pairwise post hoc anal-
ysis. All analyses were performed using Sigma Stat 3.5
(Systat Software, Inc., San Jose, CA) and basic statistics
on Microsoft Excel 2007 (Microsoft, Seattle, WA). Results
are expressed as averages  SE, with statistical signifi-
cance defined as P  0.05.
Results
C26 Adenocarcinoma–Induced Cachexia in
BALB/c Mice Results in Cardiac Atrophy
To determine whether NF-B inhibition might be cardio-
protective during cancer-induced cardiac atrophy, we
used the C26 adenocarcinoma murine model of cancer-
induced cachexia, which has been extensively charac-
terized over the past 30 years.5 Nine groups of mice were
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untreated control, a DMSO control sham, and a mutant
NBD peptide in DMSO sham), three groups of increasing
NBD peptide doses, and three groups of increasing
Compound A doses. The C26 adenocarcinoma cell line
was injected into the back flank at day 0 and allowed to
implant and grow for 5 days; the respective treatments
were begun on day 6. Daily treatment with either NBD
peptide or Compound A protected against total body
weight loss (Figure 1, A and B). In tumor-burdened ani-
mals, the measured whole left ventricular (LV) mass/tibia-
length ratio decreased 24.3% compared with control
hearts (3.1 mg/mm versus 4.1 mg/mm) after 17 days,
indicating significant cardiac atrophy (Supplemental Ta-
ble S1 at http://ajp.amjpathol.org).
Compound A and NBD Peptide Protect against
Tumor-Induced Loss of Cardiac Mass and
Decreased Systolic Dysfunction
Seventeen days after the implantation of the C26 tumors,
echocardiography and histological analysis were per-
formed on all nine groups of animals. Daily treatment with
10 mg/kg of Compound A prevented the loss of cardiac
mass after 17 days (4.1 mg/mm versus 3.1 mg/mm in
sham mice and 4.1 mg/mm in control) (Supplemental
Table S1 at http://ajp.amjpathol.org). Tumor-burdened an-
imals receiving daily mutant NBD peptide sham lost
26.8% of total heart weight (3.0 mg/mm versus 4.1mg/mm in control mice), which contrasted with mice
treated with 500 g of NBD peptide, who had hearts that
maintained their baseline heart weight, actually exceed-
ing the weight of sham controls by 9.7%. Structural as-
sessment of the left ventricular mass using echocardiog-
raphy identified similar trends of protection by the NBD
peptide and Compound A. By LV mass determination,
sham-treated groups underwent a significant loss in
mass, which was prevented with daily treatment with
Compound A or NBD peptide (Figure 2A). This was re-
flected in preserved anterior and posterior wall thickness
(Figure 2, B–D). Compound A was protective in a dose-
dependent manner, whereas all doses of NBD tested
exerted approximately the same protection (Figure 2).
To demonstrate that these changes in wall thickness
reflected changes in cardiomyocyte size, we determined
the cardiomyocyte cross-sectional area of control, tumor,
NBD peptide–treated, and Compound A–treated hearts
(Figure 3, A and B). We found that the tumor-induced loss
of cardiomyocyte area was prevented with either NBD or
Compound A treatment. Interestingly, treatment with the
highest level of Compound A (10 mg/kg) for 11 days in
tumor-challenged mice promoted a significant increase
in cardiomyocyte size compared to sham control hearts
(Figure 3B). Tumor-induced atrophic hearts displayed a
significant decrease in cardiac function (Figure 3, C and
D), consistent with previous data demonstrating that
many of the proinflammatory cytokines released during
cancer cachexia, such as IL-1, IL-6, and TNF-, directly
Figure 2. Tumor-induced cardiac atrophy is in-
hibited using therapeutics inhibiting NF-B sig-
naling by targeting IB. A: Conscious echocar-
diographic analysis of left ventricular mass
normalized to tibia length. LV mass (index) 
[1.055 * ((ExLVD;d)3  (LVEDD;d)3); where
ExLVD  external left ventricle dimension and
LVEDD  left ventricle end-diastolic dimension.
*P  0.01 versus Tumor or Tumor  NBD Con-
trol; †P  0.02 versus Tumor  Compound A 2
mg/kg; §P  0.05 versus Tumor  Compound A
5 mg/kg; #P  0.05 versus Sham; and ##P  0.02
versus Tumor NBD Peptide 500 g. B: Repre-
sentative M-mode echocardiographic tracings.
C: Anterior wall thickness. *P  0.01 versus Tu-
mor or TumorMutant NBD Control; ¶P 0.05
versus Tumor  2 mg/kg Compound A; and
†P  0.05 versus all other groups. D: Posterior
wall thickness of the heart in vivo. *P  0.01
versus Tumor or Tumor  Mutant NBD Control;
and †P  0.05 versus all other groups.induce cardiac dysfunction.30 Treatment with both Com-
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diac dysfunction, as evidenced by improvement in both
fractional shortening (Figure 3C) and ejection fraction in
treated hearts (Figure 3D). These findings demonstrate thatNF-B inhibition, using either NBD peptide or Compound A
treatment, can prevent tumor-induced cardiac dysfunction
in addition to preventing the cardiac atrophy normally as-
Figure 3. A: Histological analysis of cardiomyocytes
cross-sectional area and gross histological represen-
tation of control, tumor, and tumors treated with
either 500 g of NBD peptide or 10 mg/kg of Com-
pound A. B: Calculated cross-sectional areas of con-
trol, tumor, and tumors treated with either 500 g of
NBD peptide or 10 mg/kg of Compound A. Each
cross-sectional area was determined from 300 mea-
surements per group from at least 10 sections from 2
to 4 mice/group. *P  0.01 versus Tumor; and †P 
0.05 versus all other groups. C: Echocardiography
determination of fractional shortening percentage. *P
0.01 versus Tumor or Tumor  NBD Control; †P 
0.05 versus Tumor  2 mg/kg; and §P  0.05 versus
Tumor  5 mg/kg. D: Echocardiographic determina-
tion of ejection fraction percentage. *P  0.01 versus
Tumor or Tumor  NBD Control; †P  0.02 versus
Tumor  2 mg/kg; §P  0.05 versus Tumor  5
mg/kg; and ¶P  0.05 versus Sham. E: Quantitative
real-time PCR analysis of MHC mRNA and (F) ANF
mRNA. A one-way analysis of variance was per-
formed to determine significance, followed by a mul-
tiple comparison procedures (Holm-Sidak method)
to determine significance between groups.sociated with cancer cachexia.
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Tumor Cachexia–Induced Loss in
Cardiomyocyte Size
In hearts treated with the highest dose of Compound A
(10 mg/kg), increases in both anterior and posterior wall
thickness (Figure 2) and cardiomyocyte area (Figure 3, A
and B) were greater than that seen in non-tumor controls,
suggesting that the cardioprotective mechanism of com-
pound A may involve more than just prevention of tumor-
induced cardiac atrophy. These increases in cardiomyo-
cyte size and LV anterior and posterior wall thickness,
however, did not correlate with an increase in cardiacmass,
as shown by LV mass/tibia length (Figure 2A) or heart
weight/body weight (see Supplemental Table S1 at http://
ajp.amjpathol.org). Without an increase in LV and total
heart mass, the apparent increase in cardiomyocyte
cross-sectional area and increased LV wall thickness in
response to Compound A in mice challenged with tumor
could not be interpreted as cardiac hypertrophy. Our
interpretation of these findings are that Compound A may
have had an effect on cardiomyocyte relaxation, allowing
the cardiomyocytes and heart wall to appear larger, while
no change in heart mass was seen.
To further rule out that there was not an activation of a
pathological cardiac hypertrophy program, we investi-
gated how both Compound A and NBD affected mRNA
levels of fetal genes commonly up-regulated in patholog-
ical cardiac hypertrophy. Complicating the interpretation
of these findings is the fact that these same “fetal gene”
pathways have previously been described to increase in
models of cardiac atrophy.31 At day 17 after tumor im-
plantation, cardiac -myosin heavy chain (MHC) and
atrial natriuretic factor (ANF) mRNA were not significantly
increased in groups receiving a tumor (Figure 3, E and F).
Cardiac BNP and smooth muscle actin, however, actually
decreased in the presence of tumor in our model (see
Supplemental Figure S1 at http://ajp.amjpathol.org). De-
spite the lack of statistical significance, some individual
animals had increases in -MHC beyond the tumor-re-
lated increases that were identified in the highest doses
of Compound A (10 mg/kg). And both -MHC and ANF
mRNA levels were increased in some animals with tumor,
especially at the 80-g dose of NBD, but NBD peptide
appeared to enhance ANF mRNA levels beyond the tu-
mor alone (Figure 3, E and F). These findings reveal that
Compound A and NBD peptides may differentially regu-
late the expression of specific genes associated with
pathological cardiac hypertrophy and atrophy.31,32 How-
ever, these changes are not statistically significant and
do not consistently show increases consistent with hyper-
trophy. When either Compound A or NBD peptide treat-
ment is given in the absence of tumor for the 11 days
duration used in these studies, no apparent increase in
LV wall thickness is induced in additional studies (see
Supplemental Table S2 at http://ajp.amjpathol.org). The
Compound A–related increases in cardiomyocyte cross-
sectional area and LV wall thickness occur only in the
context of C26 adenocarcinoma–induced cachexia.
These findings are consistent with Compound A’s abilityto affect cardiomyocyte relaxation in the face of tumor
challenge, and not hypertrophy.
Both Compound A and NBD Peptide Inhibit
Tumor-Induced Increases in NF-B Activity
in Vivo
Both Compound A and the NBD peptide were given
systemically, allowing NF-B to be inhibited at the level of
the heart, skeletal muscle, or other organs. We therefore
determined how each of these therapies affected the
tumor-induced increase in NF-B activity, using an assay
to quantitatively determine the amount of nuclear p65 that
specifically recognized the p65 binding site. Nuclear ex-
tracts were prepared from freshly harvested hearts and
subsequently assayed for the amount of p65 recognizing
its response element (see Materials and Methods for de-
tails). We identified that tumor challenge increased
NF-B activity over threefold (Figure 4A). Tumor chal-
Figure 4. Compound A and NBD peptide inhibit cardiac NF-B activity.
A: NF-B activity was determined by assaying cardiac nuclear extracts for
the ability to bind NF-B response elements using an ELISA-based assay,
and identifying p65 binding (see Materials and Methods for details). At
day 17, tumor-induced increases in NF-B are inhibited significantly by
Compound A (10 mg/kg) and the NBD peptide (500 g). *P  0.02 versus all
other groups. n  4/group. B: Compound A (CA) and NBD peptide treatment
reduced cardiac NF-B mRNA after 11 days of treatment (day 17). *P  0.05
versus Ctrl; †P  0.05 versus Tumor; and §P  0.05 versus Mut NBD Peptide.
n  3/group. A one-way analysis of variance was performed to determine
significance, followed by a multiple comparison procedure (Holm-Sidak
method) to determine significance between groups.lenge in the presence of the highest levels of Compound
tly incr
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this activity (Figure 4A). In additional experiments, we
identified the expression of the gene Nfkbia, a gene reg-
ulated by NF-B as another surrogate of cardiac NF-B
activity.33 Consistent with our NF-B activity assay, we
identified that the tumor-induced increases in Nfkbia were
inhibited by the higher two doses of Compound A and by
all three doses of NBD peptide tested (Figure 4B). These
findings illustrate how Compound A and NBD peptides
inhibit cardiac NF-B activity, which may be one mech-
anism by which these therapies are cardioprotective.
Cardiac MuRF1 and Atrogin-1 Expression Peak
at Day 10 after Tumor Implantation
Activation of the NF-B transcription pathway by factors
inducing cachexia, such as TNF-, has been shown to be
sufficient to induce skeletal muscle atrophy, in part by
up-regulation of the ubiquitin ligases MuRF1 and Atrogin-
1.34 We recently reported that mice lacking MuRF1
(MuRF1/) were unable to undergo cardiac atrophy
induced by dexamethasone, indicating MuRF1’s signifi-
cant role in cardiac atrophy.27 We therefore assayed
levels of MuRF1 and its associated ubiquitin ligase
Atrogin-1 by real-time PCR after C26 adenocarcinoma
tumor challenge. (see Supplemental Figure S2, A and B,
at http://ajp.amjpathol.org). We identified that MuRF1 and
Atrogin-1 increased maximally by approximately day 10,
returning to baseline levels by 17 days after tumor im-
plantation. These findings describe MuRF1 and Atrogin-1
expression in cardiac atrophy for the first time, paralleling
studies in skeletal muscle,35 indicating that MuRF1 and
Atrogin-1 are significantly increased during the initiation
Table 1. NBD Peptide Treatment Does Not Inhibit Circulating C
DMSO sham
Control Tumor
TNF- 6.4  0.7 7.7  1.6*
IL-1 25.1  0.0 22.3  5.7
IL-2 10 10
IL-4 185.4  16.0 153.1  66.6
IL-5 13.8  7.1 8.65  3.5
IL-6 5.1  0.0 141.5  245*
IL-10 6.8  1.6 9.34  3.4*
IL-12p70 74.0  20.3 88.6  68.4
IL-13 10 10
IL-17 10 10
IFN- 39.6  6.7 37.1  4.1
GM-CSF 5.5  1.2 4.2  1.3
JE/MCP-1 81.0  53.1 43.0  2.7
MIP-2 10.7  2.8 8.53  2.7
VEGF 164.4  137 127.1  29.4
Serum was collected from tumor, or tumor-treated age-matched mice
A one-way ANOVA was performed to determine significance, followed b
(n  3/group, Group D, outlined in Materials and Methods section). T
stimulating factor; G-CSF, granulocyte-colony stimulating factor; JE/MCP-
VEGF, vascular endothelial growth factor.
*Significantly increased versus control animals (P  0.05); †Significanof atrophy in heart as well as skeletal muscle.NBD, But Not Compound A, Inhibits Tumor Size
But Not the Release of Tumor-Derived Cytokines
Mediating Cardiac Atrophy
The volume of the C26 adenocarcinoma tumors were
measured throughout the study in mice with and without
increasing doses of Compound A and NBD peptides
(see Supplemental Figure S3 at http://ajp.amjpathol.org).
No dose of Compound A affected the C26 tumor size
(see Supplemental Figure S3A at http://ajp.amjpathol.
org). Conversely, we identified that all three doses of NBD
peptides (80 to 500 g) resulted in a decrease in tumor
volume (see Supplemental Figure S3B at http://ajp.
amjpathol.org). We therefore tested the circulating cyto-
kine levels in both control and tumor-challenged mice
with and without NBD treatment (Table 1). Although we
identified tumor-induced increases in circulating TNF-,
IL-6, and IL-10, we did not find that NBD inhibited these
circulating cytokines. In fact, we found significant in-
creases in IL-6 and MIP-2 in tumor-treated mice given
500 g of NBD peptide compared to tumors alone (Table
1). Despite NBD-mediated decreases in tumor size, the
cytokines mediating cardiac atrophy were not de-
creased. This suggests that both Compound A, and likely
NBD, exerted most of its protective effects by inhibiting
atrophy at the level of the heart.
Discussion
NF-B exists as a heterodimer of two subunits (p65 and
p50), which are sequestered in an inactive form in the
cytoplasm by the repressor molecule inhibitory B
(IB). When activated by cytokines such as IL-1, IL-6,
TNF, or other tumor-related factors, the IKK complex,
composed of IKK, IKK, and IKK (NEMO) subunits,
ine and Cytokine Levels (Reported as pg/ml) at Day 17
NBD peptide treatment
80 g 200 g 500 g
7.0  1.5 7.4  1.4 7.3  1.3
24.5  4.5 20.3  5.0 20.3  3.8
10 10 10
25.4  12.8 126.6  7.2 124  14.6
10.1  2.7 8.4  2.9 9.1  3.9
91.6  822 361.1  228 378.2  309†
14.6  6.6 12.1  4.5 12.7  5.5
38.0  152 440.2  829 92.9  50.1
10 10 10
10 10 10
35.6  5.9 33.4  3.2 34.3  3.5
7.0  6.0 18.4  32.6 3.5  1.5
48.6  50.0 56.5  74.9 81.0  53.1
10.3  1.8 10.0  1.3 10.3  1.2†
738  1173 2601  5257 381.1  587
after tumor implantation and treated with NBD or control peptide (SE).
-Sidak pairwise comparison to determine significance between groups.
mor necrosis factor alpha; GM-CSF, granulocyte macrophage colony
cyte chemotactant protein-1; MIP-2, macrophage inflammatory protein-2;
eased versus tumor-bearing animals (P  0.05).hemok
1
9
2
17 days
y a Holm
NF-, tu
1, monophosphorylates IB. Once phosphorylated, IB is tar-
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teasome, allowing translocation of NF-B to the nucleus,
and subsequent transcription of a number of pro-inflam-
matory cytokines. Traditionally, broad inhibition of the
proteasome has been one way in which NF-B activity
has been inhibited. However, due to the vital nature of the
proteasome in maintaining key cellular processes and
protein quality control in the heart,36,37 proteasome inhi-
bition is not an efficient way to protect the heart against
atrophy, and has been associated with lethal cardiac
side effects.38 This led to our study of the efficacy of
novel NF-B–specific compounds in cancer-induced car-
diac atrophy.
The molecular mechanisms by which Compound A
and NBD peptides act to specifically inhibit NF-B acti-
vation have been determined at the molecular level.
Compound A is a small ATP-competitive inhibitor that
selectively targets IKK to inhibit its phosphorylation and
degradation in cells.39 Moreover, Compound A’s inhibi-
tion is focused on stress-induced NF-B activation, but
not basal levels of NF-B activation.39 Similarly, the NBD
peptides used in this study have been shown to block the
association of NEMO (IKK) and the IKK complex, which
prevents the phosphorylation and degradation of the IKK
complex.40 Similar to Compound A, the NBD peptide
potently inhibits stress-induced NF-B activation without
affecting basal NF-B activity.40 The strategies these
molecules employ are distinctly different from protea-
some inhibitors, which also inhibit NF-B activity, among
many other cellular processes. Proteasome inhibitors
used to treat myeloma, for example, block basal NF-B
activity41 and prevent a host of vital ubiquitin proteasome
functions from occurring,42–45 and can result in signifi-
cant cardiac side effects and lethality in humans.38
In the present study, we identified that Compound A
inhibited cardiac atrophy without affecting tumor growth.
We also found that NBD inhibited cardiac atrophy without
affecting circulating levels of tumor-derived cytokines
(Table 1), although it had an effect on tumor size (see
Supplemental Figure S3 at http://ajp.amjpathol.org). Since
many studies have established these tumor-derived cir-
culating cytokines, such as IL-6, as the main mechanism
by which C26 adenocarcinoma induces atrophy in mice
and human disease, the mouse models used in these
studies were ideal to test the efficacy of novel NF-B
inhibitors in protecting against cancer-induced cardiac
atrophy. We identified that these inhibitors were able to
inhibit cardiac NF-B activation in the heart, to potently
prevent cancer-induced dysfunction and atrophy.
Several recent studies from our laboratory and others
have demonstrated the therapeutic potential of inhibiting
cardiac NF-B; the use of the IKK inhibitor Compound A
used in the present study has been reported to be cardio-
protective in inhibiting ischemia reperfusion injury and in
promoting the regression of pressure overload–induced
cardiac hypertrophy.46,47 The use of cell-permeable NBD
peptides has shown efficacy in inhibiting disease in models
of pancreatitis, synovitis, and inflammatory colitis.48–52 In
the present study, both Compound A and the NBDpeptides
demonstrated cardioprotection against tumor-induced car-
diac atrophy and cardiac dysfunction in vivo. Although theactivity of these therapeutics is quite specific, we did con-
firm that both drugs inhibited cardiac NF-B activity in the
presence of tumor (Figure 4, A and B).
Proinflammatory cytokines, including TNF, are potent
inducers of the ubiquitin ligases MuRF1 and Atrogin-1.35
Moreover, recent studies have implicated NF-B, which
is activated by proinflammatory cytokines, including TNF,
in the regulation of these ubiquitin ligases.10,34 Therefore, it
is plausible that NF-B inhibition prevented the up-regula-
tion of MuRF1 and Atrogin-1. However, these ubiquitin
ligases are regulated by other transcription factors such
as FOXO53–55 and have not been good indicators of
muscle proteolysis/atrophy.56 Therefore, future studies
will need to focus on genetically altered mice, such as
MuRF1/ and Atrogin-1/ mice, to delineate their
role in mediating Compound A and NBD cardioprotective
effects in vivo.
Although both Compound A and NBD specifically in-
hibit IKK, it is important to point out that non–NF-B tar-
gets of IKK have recently been described, including
FOXO3a,57 mTOR,58 A20,59 and p53.60 Constitutive ex-
pression of IKK in primary tumor cells has been re-
ported to increase cell proliferation and the development
of tumors, which can be attenuated by expression of
FOXO3a, implicating IKK’s regulation of FOXO3a.57 In
prostate cancer cells, IKK has been shown to interact
with mTOR, as part of the TORC1 complex, to efficiently
induce mTOR activity when constitutive Akt activation is
present.58 Recent studies have also described that IKK
phosphorylates A20 in vitro and in vivo at serine 381, to
enhance A20’s ability to inhibit NF-B signaling, repre-
senting a feedback loop that attenuates NF-B signaling
following activation.59 IKK has recently been shown to
phosphorylate p53 at serines 362 and 366, which leads
to its being targeted by -TrCP1 for ubiquitination.60
These studies identified blocking IKK as a way to sta-
bilize p53 and modulate its biological activity, vital to
tumorigenesis. Although the identification of these non–
NF-B targets of the IKK complex have been made in
cancer, FOXO3a, p53, and mTOR are signaling path-
ways that have been implicated in muscle atro-
phy,16,61–65 so it is important to leave the possibility that
the beneficial effects identified in the present study may
be due to the drug’s effects on one of these other signal-
ing pathways, in addition to NF-B.
Our findings suggest that NF-B inhibition targeting
the IB complex is able to protect against cancer-
associated cardiac atrophy and dysfunction by inhib-
iting the cytokine-induced NF-B activity in the heart.
Our findings highlight the therapeutic potential of these
drugs in treating the associated cardiac morbidity re-
lated to cancer-associated cachexia beyond their pro-
tective affects against the loss of lean body mass and
fat mass.
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